According to a current one Press releaseOver half of the patients with Parkinson’s disease (PD) who participated in a survey reported a “beneficial clinical effect” from medicinal cannabis. Research into the benefits of medicinal cannabis for Parkinson’s disease has been strongly supported by organizations such as the Michael J. Fox Foundation.
The German survey was published in the Journal of Parkinson. Over eight percent of patients with Parkinson’s reported using cannabis products, and more than half of those users (54 percent) reported a beneficial clinical effect. Respondents completed over 1,300 questionnaires, and the results showed a great deal of interest within the PD community in medical cannabis.
Respondents’ knowledge of medicinal cannabis was – let’s just say – limited. Fifty-one percent of respondents were aware that medicinal cannabis is legal in many countries, and 28 percent were aware of the different methods of delivery. Interestingly, only nine percent were aware of the difference between THC and CBD.
“Our data confirm that PD patients have a keen interest in medical cannabis treatment, but have no knowledge of how it is used, and in particular the differences between the two main cannabinoids, THC and CBD,” noted Professor Dr. Bogeyman. “Doctors should consider these issues when advising their patients about treatment with medicinal cannabis. The data reported here can help clinicians decide which patients might benefit, what symptoms might be treated, and what type of cannabinoid and which route of administration might be appropriate. “
The Michael J. Fox Foundation advocates several medical cannabis bills This would allow more research into the use of cannabis to treat Parkinson’s. “Preclinical work, including several MJFF-funded studies, shows that cannabinoids can protect brain cells through antioxidant and anti-inflammatory mechanisms.” Rachel Dolhun, MD wrote on the foundation’s website.
“Clinical studies have looked at whether marijuana can relieve the motor and non-motor symptoms of Parkinson’s Levodopa-induced dyskinesia, involuntary movements that can lead to long-term use of levodopa and long life with Parkinson’s disease. “